Nipro PharmaPackaging is expanding the manufacturing capacity of pre-fillable glass syringes at its dedicated German plant in Münnerstadt by 30%.
This capacity expansion over the coming two years marks the next phase in Nipro PharmaPackaging’s ambitious long-term growth strategy for pre-fillable glass syringes. Embedded in the plan are the required infrastructure, including a 5000m² new production hall and classified clean rooms, which had been foreseen and built at an earlier stage. This now allows the timely installation of new high-tech glass forming, needle bonding as well as D2F™ (Direct-to-Fill) syringe lines in the state-of-the-art manufacturing site in Münnerstadt.
The current expansion will provide the means to meet the rising demand for syringe-based injection systems. Plus, it will also contribute to the timely delivery of drugs, and ultimately to the well-being of patients.
Nipro's recent initiatives to increase capacity in France and in the US in its production of borosilicate glass tubing feeds into the surge in demand.
The Münnerstadt plant, logistically well-located in the heart of Europe, is the center of excellence for high-quality pre-fillable glass syringes. The plant complies to the strictest quality standards: ISO 9001, ISO 15378, ISO 50001, ISO 45001, ISO 14001, and ISO 14644. D2F™ syringes are offered in different qualities, meeting the requirements from prevailing drug products up to biotech products alike.
Driven by customer centricity, dedicated and experienced teams offer comprehensive support for technical-, quality-, and regulatory-related inquiries.
The extensive experience, premium quality products, and comprehensive support is reflected by trusted, long-term partnerships with leading pharmaceutical companies.
